BIVV009

Phase 3Small molecule

BBioverativ, a Sanofi company

BIVV009 is one of 50 small molecule programs targeting Immune Thrombocytopenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune ThrombocytopeniaActive, not recruiting

Cold Agglutinin DiseaseActive, not recruiting

Immune ThrombocytopeniaPhase 1

Active, not recruiting

Cold Agglutinin DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

135 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Nplate

Amgen

Phase 3

8 2

Rysodeg

UCB

Phase 3

3 3

Cellcept

Roche

Phase 3

2 4

Vyvgart

Argenx

Phase 3

6 5

Doptelet

AAkarx

Phase 3

6 6

Fabhalta

Johnson & Johnson

Phase 3

—7

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

3 8

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

3 9

Avlosulfon

AAlmirall, S.A.

Phase 3

1 10

Tamiflu

CConrado Roberto Hoffmann Filho

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immune Thrombocytopenia1 trial

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

Completed·BBioverativ, a Sanofi company·Phase 1·NCT03275454·12 enrolled

Cold Agglutinin Disease1 trial

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)

Completed·BBioverativ, a Sanofi company·Phase 3·NCT03347396·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BIVV009. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BIVV009 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BIVV009. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bioverativ, a Sanofi company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBioverativ, a Sanofi company

BIVV009

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Cold Agglutinin Disease1 trial

References

Drug Info

Quick Facts

Related News